Differentiating primary pathophysiologic from secondary adaptational processes

Depression and Anxiety

Volumn 14, Issue 2, 2001, Pages 105-111

  Levine, Joseph ^a,b   Chengappa, K N Roy ^a   Gershon, Samuel ^a   Drevets, Wayne ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MENTAL HEALTH CENTER   (Israel)

Author keywords

Adaptation, physiological; Amygdala; Anxiety; Depression; Receptors, interleukin 2

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; INTERLEUKIN 2 RECEPTOR; PHENELZINE; PLACEBO; REBOXETINE;

ADAPTATION; AMYGDALOID NUCLEUS; ANXIETY NEUROSIS; DEPRESSION; DRUG EFFECT; EMOTION; HUMAN; MENTAL DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA;

ADAPTATION, PSYCHOLOGICAL; AMYGDALA; ANIMALS; ANXIETY DISORDERS; DEFENSE MECHANISMS; DEPRESSIVE DISORDER, MAJOR; HUMANS; RECEPTORS, INTERLEUKIN-2;

EID: 0034791129     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.1052     Document Type: Review

References (84)

1. Impaired declarative memory for the emotional material following bilateral amygdala damage in humans
2. Interteukin 1 and interleukin 2 enhance propiomelanocortin gene expression in pituitary cells
3. Amygdala enlargement in bipolar disorder and hippocampal reduction in schizophrenia: A MRI study demonstrating neuroanatomic specificity
4. Anatomical organization of the primate amygdaloid complex
5. Chronic treatment with the antidepressant amitryptiline decreases CRF-R1 receptor mRNA in the rat amygdala
6. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients
7. Biochemical hypotheses of mood and anxiety disorders
8. The microglial cell a historical review
9. The functional neuroanatomy of major depression: An fMRI study using an emotional activation paradigm
10. Cerebral glucose metabolism in women with panic disorder
11. Neural responses to sad and angry expressions
12. Psychbiologic mechanisms of posttraumatic stress disorder
13. Forced swim test-induced neurochemical endocrine and immune changes in rat
14. Anatomic and physiological substrate of emotion in an animal model
15. Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex possible relevance to PTSD
16. Effects of antidepressant treatment on inhibitory avoidance behavior and amygdala beta-adrenoreceptors in rats
17. Reciprocal suppression of regional blood flow during emotional versus higher cognitive processes: Implications for interactions between emotions and cognition
18. Subgenual prefrontal abnormalities in mood disorder
19. Prefrontal cortical amygdalar metabolism in major depression
20. Neuroanatomical circuits in depression: Implications for treatment mechanisms
21. Effects of antidepressant drugs injected into the amygdala on behavioral responses of rats in the forced swim test
22. Role of the basolateral nucleus of the amygdala in the formation of phobia
23. Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides
24. Increased soluble interleukin 2 receptor levels in schizophrenia
25. The effect of antidepressant drugs on regional cerebral glucose utilization in the rat
26. Comorbidity of depression and panic disorder
27. HMPO SPECT brain imaging in resistant depression
28. The amygdala and depression
29. 5-HT uptake and 5-HT2 receptors in brain of antidepressant free suicide victims/depressives: Increase in 5-HT2 sites in cortex and amygdala
30. Initiation and adaptation: A paradigm for understanding psychotropic drug action
31. Toward a neuroanatomy of obsessive-compulsive disorder
32. Emotional states and feelings
33. Research on tolerance: What can we learn from history?
34. The primate amygdala mediates avute fear responses but not behavioral and physiological responses associated with anxious/feqarful temperament
35. Major depression and generalized anxiety disorder. Same genes, (partly) different environments?
36. Haloperidol does not affect the level of serum-soluble interleukin-2 receptor in drug free male schizophrenics
37. The amygdala and social behavior
38. Late-onset evidence for common neuroanatomical substrats detected by using MRI
39. Human amygdala activation during conditioned fear acquisition and extinction: A mixed trial fMRI study
40. Introduction to section IX: Emotions
41. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
42. Psychoimmune investigation in obsessive-compulsive disorder: Assays of plasma transferrin, IL-2 and IL-6 receptor, and IL-1 beta and IL-6 concentrations
43. Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine
44. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression
45. Increases in CSF levels of interleukin 2 in schizophrenia: Effects of recurrence of psychosis and medication status
46. Cortical pathways to the mammalian amygdala
47. Induction of Fos-like-immunoreactivity in the central extended amygdala by antidepressant drugs
48. A differential neural response in the human amygdala to fearful and happy facial expression
49. Neuroleptic treatment increases soluble IL-2 receptors and decreases in soluble IL-6 receptors in schizophrenia
50. Cerebral glucose metabolic differences in patients with panic disorder
51. Neuroimaging of human anxiety
52. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels
53. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol
54. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors
55. Neural plasticity and emotional memory
56. Behind the scenes of functional brain imaging: A historical and physiological perspective
57. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia
58. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients
59. Serum cytokine and soluble interleukin-2 receptors in patients with panic disorder
60. Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia
61. The application of positron emission tomography the study of panic disorder
62. Immunological dysfunction in schizophrenia: A systematic approach
63. Search for pathophysiology of panic disorder
64. The soluble interleukin-2 receptor: Biology, function, and clinical application
65. Role of corticotropin-releasing factor and urocortin with the basolateral amygdala of rats in anxiety and panic responses
66. Neurophysiological assessment of brain function and maturation: A measure of brain adaptation in high risk infants
67. Cytokine production and serum prolactin in depression
68. Role of the basolateral amygdala in panic disorder
69. Amygdala core volumes are decreased in recurrent major depression
70. Visual imagery and perception in posttraumatic stress disorder a positron emission tomographic investigation
71. Elevated levels of serum interleukin-1 beta in combat-related posttraumatic stress disorder
72. The psychophysiology of depression and anxiety
73. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder
74. Adaptation to acute and chronic hyponathremia: Implications for symptomatology, diagnosis and therapy
75. Death and the internal milieu: Claude Bernard and the origins of experimental medicine
76. Effects of sleep deprivation on brain metabolism of depressed patients
77. Hughling Jackson's theory of recovery